Skip to main content
Premium Trial:

Request an Annual Quote

SC Biosciences, Cyntellect, Cenix, Bayer, Northwestern U, Cambria

Premium

SC Biosciences to Exclusively Distribute Cyntellect's LEAP System in Japan; Equity Investment Sweetens Deal

SC Biosciences, a subsidiary of Japanese trading company Sumitomo, will exclusively distribute Cyntellect's LEAP automated cell imaging and processing system and related collaborative services in Japan, the companies said last week.

SCB has also made an equity investment in Cyntellect and has ordered several LEAP units. The companies plan to ship the first instruments to Japan beginning in early 2006.

LEAP, which stands for laser-enabled analysis and processing, combines high-speed optical imaging of cells with real-time image analysis and high-speed laser manipulation of individual live cells in microplates.

Cyntellect, based in San Diego, said it will evaluate other potential commercial partners for LEAP for further geographic areas.


Cenix Delivers Drug Targets to Bayer, Receives Milestone Payment

Cenix Bioscience announced last week that it has delivered to partner Bayer a collection of potential drug targets, which were identified using RNAi.

According to Cenix, the targets were identified as part of a December 2003 RNAi-based discovery collaboration in which cell-based assays originally developed by Bayer were adapted and optimized by Cenix to be run as high-throughput RNAi screens.

Under the terms of the collaboration, Bayer acquired the first option to secure all rights to new target-related intellectual property generated by the project. According to Cenix, Bayer has sought patent protection on the targets just delivered, triggering an undisclosed milestone payment to Cenix.


Northwestern U Wins Drug Screening Grant from ALS Association; Cambria to Collaborate

The ALS Association last week announced funding for a project headed by Northwestern University researcher Richard Morimoto to screen for new amyotrophic lateral sclerosis therapies.

The project will screen for compounds that interact with mutant forms of an ALS-associated protein in Caenorhabditis elegans models.

Cambria Biosciences, based in Woburn, Mass., will also take part in the collaboration to carry high-throughput screening of several compound libraries.

The amount of the funding was not disclosed.


Note to Subscribers:
Cell-Based Assay News will not publish on Aug. 22. The next issue of the newsletter will appear on Aug. 29.
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.